Due to its high and specific cytotoxicity, synergistic treatment with the non-toxic targeted toxin EGF-PE24mutΔREDLK and SO1861 represents a new promising strategy for the future therapy of advanced prostate cancer. The gene discussed is EGF; the disease is prostate cancer.